Skip to content
HowShorted

Aimmune Therapeutics, Inc. short interest in 2018

In 2018, Aimmune Therapeutics, Inc.'s disclosed short interest ran from 5.15% of shares outstanding on 12 Jan 2018 to 11.31% on 31 Dec 2018, a change of +6.16 percentage points. The year's high was 11.31% on 31 Dec 2018 and its low 5.04% on 15 Feb 2018, averaging 8.78% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 21.44 days on 13 Jul 2018. Full history: Aimmune Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020

Aggregate net short position time series for Aimmune Therapeutics, Inc. in 2018

2018 in figures

Start of year
5.15% (12 Jan 2018)
End of year
11.31% (31 Dec 2018)
Change
+6.16 pp
High
11.31% (31 Dec 2018)
Low
5.04% (15 Feb 2018)
Average
8.78%
Highest days to cover
21.44 (13 Jul 2018)
SEC filings marked
8

Every report in 2018

Aimmune Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20185.15%6.68
31 Jan 20185.10%5.75
15 Feb 20185.04%5.63
28 Feb 20187.51%1.2410-K filed
15 Mar 20188.13%3.37results (8-K)
29 Mar 20189.12%4.68
13 Apr 20188.82%5.96
30 Apr 20188.45%11.98
15 May 20188.79%10.7110-Q filed, results (8-K)
31 May 20188.67%10.57
15 Jun 20188.93%9.26
29 Jun 201810.18%7.94
13 Jul 201810.13%21.44
31 Jul 20189.88%17.41
15 Aug 20189.48%17.0310-Q filed, results (8-K)
31 Aug 20189.05%16.17
14 Sep 20189.65%10.61
28 Sep 20188.62%9.71
15 Oct 20189.43%13.10
31 Oct 20189.82%14.17
15 Nov 20189.60%6.3710-Q filed, results (8-K)
30 Nov 201810.12%6.88
14 Dec 20189.84%9.45
31 Dec 201811.31%6.19

See also: Aimmune Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.